Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | COPS5 | Q92905 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29063447 | 0.84 | KDM4E (0.47) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL2082444 | 0.82 | ALDH1A1 (0.65) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL6284882 | 0.81 | NPSR1 (0.47) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL15652654 | 0.80 | COPS5 (0.44) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL353509 | 0.80 | COPS5 (0.58) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL12292842 | 0.80 | COPS5 (0.44) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL4129141 | 0.77 | FBP1 (0.62) | ALDH1A1COPS5CYP1A2FBP1 | |
| SCHEMBL14820153 | 0.77 | NPSR1 (0.42) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL8071199 | 0.77 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL794531 | 0.77 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2025-01-02 | — | — | US | disclosed |
| CN-108383858-B | Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation | 百时美施贵宝公司 | 2024-09-20 | — | — | CN | disclosed |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3632919-B1 | PHARMACEUTICAL COMPOISITIONS COMPRISING IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2022-10-26 | — | — | EP | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3243826-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-1389202-A1 | 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Pharmaceuticals Corporation (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6660752-B2 | Adrenergic blocking agents | BAYER PHARMACEUTICALS CORPORATION | 2003-12-09 | — | — | US | disclosed |
| US-20030195352-A1 | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| EP-1343778-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003059881-A2 | DNA MINOR GROOVE BINDING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2003-07-24 | — | — | WO | disclosed |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| WO-2003024948-A1 | BENZOFURAN AND DIHYDROBENZOFURAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002085891-A1 | 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002048134-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | ALDH1A1 2559/4885KDM4E 3170/4885SMN1; SMN2 4297/4885 |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | ALDH1A1 2559/4885KDM4E 3170/4885SMN1; SMN2 4297/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | ALDH1A1 2611/4885KDM4E 3172/4885SMN1; SMN2 4341/4885 |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ALDH1A1 1358/4885KDM4E 4345/4885SMN1; SMN2 1888/4885 |
| US-20030195352-A1 | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | ALDH1A1 106/4885KDM4E 4527/4885SMN1; SMN2 1597/4885 |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, F2R, TMPRSS4 | ALDH1A1 2611/4885KDM4E 3172/4885SMN1; SMN2 4341/4885 |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | ALDH1A1 1696/4885KDM4E 2936/4885SMN1; SMN2 3858/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | ALDH1A1 2559/4885KDM4E 3170/4885SMN1; SMN2 4297/4885 |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | ALDH1A1 2524/4885KDM4E 3131/4885SMN1; SMN2 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.